S 64315

Drug Profile

S 64315

Alternative Names: MIK 665; S64315

Latest Information Update: 17 Dec 2016

Price : $50

At a glance

  • Originator Servier; Vernalis
  • Developer Novartis; Servier; Vernalis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action MCL1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Lymphoma; Multiple myeloma; Myelodysplastic syndromes

Most Recent Events

  • 12 Dec 2016 Preclinical trials in Lymphoma in France (IV) before December 2016
  • 12 Dec 2016 Preclinical trials in Multiple myeloma in France (IV) before December 2016
  • 12 Dec 2016 Novartis Pharmaceuticals plans a first-in-human phase I trial for Lymphoma and Multiple myeloma (Second-line therapy or greater, Monotherapy) in Australia, USA, France, Germany, Italy, South Korea, Japan and Spain (IV) (NCT02992483)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top